Policy & Regulation
Codagenix's COVI-VAC vaccine Phase one dose escalation trial results indicate safety and immunogenicity
23 September 2021 -

Codagenix Inc, a US-based clinical-stage biotechnology company, announced on Wednesday that its novel intranasal COVI-VAC vaccine has indicated promising safety and immunogenicity results in its Phase one dose escalation trial in healthy adults.

Data indicated that the product is likely to block replication of the SARS-CoV-2 virus in the nose. These clinical data, combined with pre-clinical data showing COVI-VAC to be efficacious against a variant of concern, suggest the vaccine has the potential to generate broad immunity against COVID-19. The product is a live-attenuated vaccine candidate produced utilising the company's machine-learning enabled codon deoptimization vaccine design platform that relies on a combination of computational science and synthetic biology to produce systematically attenuated viral vaccines.

The company expects data from the full Phase one trial cohort in late third quarter or fourth quarter of 2021 and will be presenting detailed data from the trial at the IDWeek 2021 Annual Meeting, scheduled from 29 September to 3 October, which will be held virtually.